EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance

Andrew F Shorr iD, Mark E Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I Smart, Marc Engelhardt iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0326758 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Andrew F Shorr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pulmonary and Critical Care Medicine, Medstar Washington Hospital, Washington, Columbia, United States of America. Hauptthemen laut MEDLINE: Linezolid, Cephalosporins, Pneumonia, Bacterial, Community-Acquired Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basilea Pharmaceutica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ceftobiprole is an advanced-generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus , resistant pneumococci, and Enterobacterales. In a Phase 3 study in community-acquired bacterial pneumonia (CABP) performed prior to the current US Food and Drug Administration (FDA) guidance, clinical cure at the test-of-cure visit (TOC) was the primary endpoint. We present a re-analysis using early clinical success as the primary endpoint per the 2020 FDA CABP Guidance.

Methods

In this multicenter, double-blind study, patients with CABP requiring hospitalization were randomized to intravenous ceftobiprole (500 mg q8h) or ceftriaxone (2000 mg q24h) ± linezolid (600 mg q12h) for 3–14 days. The primary endpoint was clinical success at Day 3 (improvement in ≥2 symptoms of chest pain, cough, productive sputum, difficulty breathing). A 12.5% non-inferiority margin was used.

Results

Of the original 638 patients, 618 (97%) had ≥ 2 symptoms and were included in the Day 3 Intent-to-Treat (ITT) population for the re-analysis. The Day 3 modified ITT population consisted of 187 patients (29%) meeting additional FDA Guidance including Patient Outcomes Research Team (PORT) classification ≥III. Ceftobiprole was non-inferior to ceftriaxone for clinical success for Day 3 ITT (71.0% vs 71.1%) and Day 3 modified ITT (71.1% vs 66.7%) populations. The 28-day all-cause mortality was 1.6% (ceftobiprole) vs 2.6% (ceftriaxone) in the Day 3 ITT population and 2.1% vs 7.8% in the Day 3 modified ITT population.

Conclusion

Ceftobiprole was non-inferior to ceftriaxone ± linezolid for clinical success at Day 3 according to the current 2020 FDA CABP Guidance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidCephalosporinsPneumonia, BacterialCommunity-Acquired InfectionsCeftriaxoneAnti-Bacterial AgentsHumansMaleFemaleUnited StatesUnited States Food and Drug AdministrationMiddle AgedDouble-Blind MethodAgedAdultTreatment Outcome

Substanzen

LinezolidCephalosporinsCeftriaxoneAnti-Bacterial Agentsceftobiprole

Autor:innen und Institutionen

  • Pulmonary and Critical Care Medicine, Medstar Washington Hospital, Washington, Columbia, United States of America.
  • Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.

ORCID-Profile: Andrew F Shorr, Marc Engelhardt

Förderung

  • Basilea Pharmaceutica

Zitieren

APA

Shorr, A. F., Jones, M. E., Friedmann, S., Ionescu, D., Saulay, M., Smart, J. I., & Engelhardt, M. (2025). Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. PLOS One. https://doi.org/10.1371/journal.pone.0326758

Vancouver

Shorr AF, Jones ME, Friedmann S, Ionescu D, Saulay M, Smart JI, et al. Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. PLOS One. 2025. doi:10.1371/journal.pone.0326758

BibTeX
@article{Shorr2025,
  author = {Shorr, Andrew F and Jones, Mark E and Friedmann, Silke and Ionescu, Daniel and Saulay, Mikael and Smart, Jennifer I and Engelhardt, Marc},
  title = {Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0326758}
}
Kostenlos starten →